No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness

Anne B Koopmans, David J Vinkers, Igmar T Poulina, Petra J A Gelan, Ron H N van Schaik, Hans W Hoek, Peter N van Harten, Anne B Koopmans, David J Vinkers, Igmar T Poulina, Petra J A Gelan, Ron H N van Schaik, Hans W Hoek, Peter N van Harten

Abstract

Background: The CYP2D6 enzyme is involved in the metabolism of numerous psychopharmacological drugs. Guidelines recommend how to adjust the dose of medication based on the CYP2D6 genotype. Aims: To evaluate the effect of dose adjustment to the CYP2D6 genotype and phenotype, in patients with severe mental illness (SMI) already receiving psychopharmacological treatment. Methods: A total of 269 psychiatric patients (on the island Curaçao) receiving antipsychotic treatment were genotyped for CYP2D6. Of these, 45 patients were included for dose adjustment according to the clinical guideline of the Royal Dutch Association for the Advancement of Pharmacy, i.e., 17 CYP2D6 poor metabolizers, 26 intermediate metabolizers, and 2 ultrarapid metabolizers. These 45 patients were matched for age, gender, and type of medication with a control group of 41 patients who were CYP2D6 extensive metabolizers (i.e., with a normal CYP2D6 function). At baseline and at 4 months after dose adjustment, subjective experience, psychopathology, extrapyramidal side-effects, quality of life, and global functioning were assessed in these two groups. Results: At baseline, there were no differences between the groups regarding the prescribed dosage of antipsychotics, the number of side-effects, psychiatric symptoms, global functioning, or quality of life. After dose adjustment, no significant improvement in these parameters was reported. Conclusion: In psychiatric patients with SMI already receiving antipsychotic treatment, dose adjustment to the CYP2D6 genotype or phenotype according to the guidelines showed no beneficial effect. This suggests that dose adjustment guidelines are currently not applicable for patients already using antipsychotics. ClinicalTrials.gov: Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao; Identifier: NCT02713672; https://ichgcp.net/clinical-trials-registry/NCT02713672?term=CYP2D6&rank=5.

Keywords: CYP2D6; dose adjustment; genotyping; guidelines; personalized medicine; psychopharmacology; severe mental illness (SMI).

Figures

Figure 1
Figure 1
Study procedure and inclusion of participants. PM, poor metabolizer; IM, intermediate metabolizer; UM, ultrarapid metabolizer; EM, extensive metabolizer.
Figure 2
Figure 2
Prescribed dose of antipsychotics in DDD per CYP2D6 geno-/phenotype group at baseline. DDD, defined daily dose; PM, poor metabolizer; IM, intermediate metabolizer; UM, ultrarapid metabolizer; Error Bars, ±1 SD.

References

    1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. . P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6:1–423. 10.1097/00008571-199602000-00002
    1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. (2005) 5:6–13. 10.1038/sj.tpj.6500285
    1. de Leon J, Susce MT, Pan R-M, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 Poor Metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry (2005) 66:15–27. 10.4088/JCP.v66n0103
    1. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JPA. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics (2005) 15:151–8. 10.1097/01213011-200503000-00003
    1. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Mulleroerlinghausen B, et al. . The impact of the polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. (2002) 72:438–52. 10.1067/mcp.2002.127494
    1. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. (2016) 72:175–84. 10.1007/s00228-015-1965-1
    1. Kawanishi C, Lundgren S, Ågren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. (2004) 59:803–7. 10.1007/s00228-003-0701-4
    1. Ruaño G, Szarek BL, Villagra D, Gorowski K, Kocherla M, Seip RL, et al. . Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med. (2013) 7:429–39. 10.2217/bmm.13.16
    1. Swen J, Wilting I, de Goede A, Grandia L, Mulder H, Touw D, et al. . Pharmacogenetics: From Bench to Byte. Clin Pharmacol Ther. (2008) 83:781–7. 10.1038/sj.clpt.6100507
    1. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. . Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. (2011) 89:662–73. 10.1038/clpt.2011.34
    1. Müller DJ, Kekin I, Kao ACC, Brandl EJ. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry (2013) 25:554–71. 10.3109/09540261.2013.838944
    1. Thümmler S, Dor E, David R, Leali G, Battista M, David A, et al. . Pharmacoresistant severe mental health disorders in children and adolescents: functional abnormalities of cytochrome P450 2D6. Front Psychiatry (2018) 9:2. 10.3389/fpsyt.2018.00002
    1. Goldman ML, Spaeth-Rublee B, Pincus HA. The case for Severe Mental Illness as a disparities category. Psychiatr Serv. (2018) 69:726–8. 10.1176/appi.ps.201700138
    1. West JC, Wilk JE, Olfson M, Rae DS, Marcus S, Narrow WE, et al. . Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. (2005) 56:283–91. 10.1176/appi.ps.56.3.283
    1. Covell NH, Weissman EM, Schell B, McCorkle BH, Summerfelt WT, Weiden PJ, et al. . Distress with medication side effects among persons with Severe Mental Illness. Adm Policy Ment Heal Ment Heal Serv Res. (2007) 34:435–42. 10.1007/s10488-007-0131-1
    1. Wullschleger A, Khazaal Y, Heinze M. Editorial: new models of care for patients with severe mental illness—Bridging in- and outpatients. Front Psychiatry (2018) 9:3. 10.3389/fpsyt.2018.00003
    1. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, et al. . Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. (2000) 20:246–51. 10.1097/00004714-200004000-00019
    1. Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. (2013) 113:266–72. 10.1111/bcpt.12093
    1. Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, Mcleod C. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. (2011) 11:1–14. 10.1038/tpj.2010.73
    1. Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. . The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. (2010) 14:1–157, iii. 10.3310/hta14030
    1. Müller DJ, Brandl EJ, Degenhardt F, Domschke K, Grabe H, Gruber O, et al. . Pharmakogenetik in der Psychiatrie: eine Standortbestimmung. Nervenarzt (2018) 89:290–9. 10.1007/s00115-017-0479-8
    1. Koopmans AB, Vinkers DJ, Gelan PJ, Hoek HW, van Harten PN. CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles. Pharmacogenomics (2017) 18:1003–12. 10.2217/pgs-2017-0011
    1. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, et al. . Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol. (2010) 50:450–8. 10.1177/0091270009359182
    1. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. . Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. (2012) 91:321–6. 10.1038/clpt.2011.287
    1. Guidelines for ATC Classification and DDD Assignment 2014. WHO Collaborating Centre for Drug Statistics Methodology, Oslo (2014).
    1. Dingemans PM, Winter MF, Bleeker JAC, Rathod P. A cross-cultural study of the reliability and factorial dimensions of the Brief Psychiatric Rating Scale (BPRS). Psychopharmacology (1983) 80:190–1.
    1. Gerlach J, Korsgaard S, Clemmesen P, Lund Laursen A, Magelund G, Noring U, et al. . The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validitv. Acta Psychiatr Scand. (1993) 87:244–52.
    1. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry (1989) 154:672–7.
    1. Janno S, Holi MM, Tuisku K, Wahlbeck K. Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia. Eur Neuropsychopharmacol. (2005) 15:39–41. 10.1016/j.euroneuro.2004.05.003
    1. Mulhern B, Mukuria C, Barkham M, Knapp M, Byford S, Soeteman D, et al. . Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry (2014) 205:236–43. 10.1192/bjp.bp.112.122283
    1. Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. . Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ. (2010) 88:815–23. 10.2471/BLT.09.067231
    1. Üstün T, Chatterji S, Villanueva M, Bendib L, Çelik C, Sadana R, et al. WHO Multi-Country Survey Study on Health and Responsiveness 2000-2001. GPE discussion Paper No 37. (2001).
    1. de Haan L, Weisfelt M, Dingemans P, Linszen D, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (2002) 162:24–8. 10.1007/s00213-002-1054-x
    1. Risselada AJ. Switchen van en naar depotantipsychotica. Psyfar (2012) 12:18–23.
    1. Torres US, Portela-Oliveira E, Borgwardt S, Busatto GF. Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis. BMC Psychiatry (2013) 13:342. 10.1186/1471-244X-13-342
    1. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med. (2010) 40:1409–22. 10.1017/S0033291709992297
    1. Owens DG, Johnstone EC, Crow TJ, Frith CD, Jagoe JR, Kreel L. Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychol Med. (1985) 15:27–41.
    1. Seeman P, Tinazzi M. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Prog Neuro Psychopharmacol Biol Psychiatry (2013) 44:178–83. 10.1016/j.pnpbp.2013.02.011
    1. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov. (2014) 4:1–9. 10.7916/D8MS3R8C
    1. Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, et al. . Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a Serious Mental Illness. J Clin Psychiatry (2017) 78:e279–85. 10.4088/JCP.16m11049
    1. de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, et al. . Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry (2004) 49:290–6. 10.1177/070674370404900503
    1. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry (2000) 157:514–20. 10.1176/appi.ajp.157.4.514
    1. De Andrés F, Terán S, Hernández F, Terán E, LLerena A. To genotype or phenotype for personalized medicine? CYP450 drug metabolizing enzyme genotype–phenotype concordance and discordance in the Ecuadorian population. Omi A J Integr Biol. (2016) 20:699–710. 10.1089/omi.2016.0148
    1. Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol. (2014) 79:222–40. 10.1111/bcp.12441
    1. Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: Hypothesis with implications for personalized medicine. Drug Metab Dispos. (2014) 43:400–10. 10.1124/dmd.114.061093
    1. Shah RR. Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy? Ther Adv Drug Saf. (2017) 8:267–72. 10.1177/2042098617712657
    1. Berm E, Kok R, Hak E, Wilffert B. Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry. Pharmacopsychiatry (2016) 49:186–90. 10.1055/s-0042-105443
    1. Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, et al. . Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression. J Clin Psychiatry (2013) 74:614–21. 10.4088/JCP.12m07807
    1. Preskorn SH. Prediction of individual response to antidepressants and antipsychotics: an integrated concept. Dialogues Clin Neurosci. (2014) 16:545–54.
    1. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. Am J Psychiatry (1998) 155:565–7.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir